CGTLive®’s Weekly Rewind – May 24, 2024
Review top news and interview highlights from the week ending May 24, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Atara Submits BLA for Tab-Cel EBV+ PTLD T-Cell Therapy
Tab-Cel is approved under the name Ebvallo in Europe, Switzerland, and United Kingdom.
2. Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
The Associate Professor of Neurology at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.
3. CRISPR-Editing EBT-101 Therapy Safe, Temporarily Suppresses HIV Infection
Excision is evaluating a higher dose in a second cohort as well as exploring alternative, potentially redosable, delivery methods.
4. Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical Trials
The associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.
5. NKGen’s Autologous NK Therapy Proceeds to Phase 2 Trial for Alzheimer Disease
Most participants had improved or stable cognitive function in a proof-of-concept study.
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy
June 18th 2025In honor of Alzheimer's & Brain Awareness Month, observed annually in June, we took a look back at recent news and insights in cell and gene therapy for Alzheimer disease and other dementias.
Eugenio Galli, MD, PhD, on Reexamining Frailty as a Barrier to CAR-T Treatment
June 16th 2025The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.
